Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.69 |
| ▸ | GIPR | P48546 | 15/20 | 0.69 |
| ▸ | GLP1R | P43220 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | GCG | P01275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100544 | 1.00 | GCGR (0.69) | GCGRGIPRGLP1RKMT2ANPC1 | |
| SCHEMBL2665430 | 0.90 | GCGR (0.60) | GCGRGIPRGLP1RKMT2ANPC1 | |
| SCHEMBL9070841 | 0.89 | GCGR (0.59) | GCGRGIPRGLP1RKMT2ANPC1 | |
| SCHEMBL9071075 | 0.87 | GCGR (0.57) | GCGRGIPRGLP1RKMT2A | |
| SCHEMBL2665453 | 0.87 | GCGR (0.57) | GCGRGIPRGLP1RKMT2ANPC1 | |
| SCHEMBL2654817 | 0.84 | GCGR (0.58) | GCGRGIPRGLP1R | |
| SCHEMBL2654819 | 0.84 | GCGR (0.58) | GCGRGIPRGLP1R | |
| SCHEMBL6748212 | 0.84 | GCGR (0.58) | GCGRGIPRGLP1R | |
| SCHEMBL6748214 | 0.84 | GCGR (0.58) | GCGRGIPRGLP1R | |
| SCHEMBL2666552 | 0.84 | GCGR (0.58) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.